Title:
High-quality proteins and tools for biologics development against COVID-19
Agreement Value:
$99,880.00
Agreement Date:
Jan 25, 2021 - Mar 31, 2022
Description:
This Project has two objectives:
1. Acquiring an understanding of the Covid-19 viral translocation mechanism at the molecular level. More specifically, it will investigate if/how glycosylation of the viral spike protein and human angiotensin converting enzyme 2 (ACE2) receptor modulates binding, and
2. How the glycan structure of the ADCC-attenuated Fc D270G mutant (Fc1X7) structure impacts interaction between Fcγ and FcRn receptors. The Fc1X7 is used as a fusion partner for COVID-19 therapeutic proteins and the information generated here will provide important information about enhancing their efficacy and safety.
Organization:
National Research Council Canada
Expected Results:
In the short term, anticipated outcomes will be strengthened collaborations across industry, academia, and government to support research excellence. In the medium term, anticipated outcomes will be the development of new and potentially disruptive technologies with collaborators. In the long term, find collaborative solutions to public policy challenges and create stronger innovation systems.
Location:
Montreal, Quebec, CA H3T 1J4
Reference Number:
172-2021-2022-Q4-964421
Report Type:
Grants and Contributions
Recipient Business Number:
107585226
Additional Information:
This agreement has been amended 1 time(s).The total amended value is 99,880 dollars and the end date of this agreements has been modified by 91 days
Amendment Date
Feb 10, 2022
Recipient's Legal Name:
Corporation de l'École Polytechnique de Montréal
Federal Riding Name:
Outremont
Federal Riding Number:
24054
Program:
Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives
Program Purpose:
Collaborate on multiparty research and development programs to catalyze transformative, high-risk, high-reward research with the potential for game-changing scientific discoveries and technological breakthroughs in priority areas.